TY - JOUR
T1 - A Validated Risk Prediction Model for Breast Cancer in US Black Women
AU - Palmer, Julie R.
AU - Zirpoli, Gary
AU - Bertrand, Kimberly A.
AU - Battaglia, Tracy
AU - Bernstein, Leslie
AU - Ambrosone, Christine B.
AU - Bandera, Elisa V.
AU - Troester, Melissa A.
AU - Rosenberg, Lynn
AU - Pfeiffer, Ruth M.
AU - Trinquart, Ludovic
N1 - Publisher Copyright:
, Copyright © 2022 American Society of Clinical Oncology. All rights reserved.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - PURPOSE Breast cancer risk prediction models are used to identify high-risk women for early detection, targeted interventions, and enrollment into prevention trials. We sought to develop and evaluate a risk prediction model for breast cancer in US Black women, suitable for use in primary care settings. METHODS Breast cancer relative risks and attributable risks were estimated using data from Black women in three US population-based case-control studies (3,468 breast cancer cases; 3,578 controls age 30-69 years) and combined with SEER age- and race-specific incidence rates, with incorporation of competing mortality, to develop an absolute risk model. The model was validated in prospective data among 51,798 participants of the Black Women’s Health Study, including 1,515 who developed invasive breast cancer. A second risk prediction model was developed on the basis of estrogen receptor (ER)–specific relative risks and attributable risks. Model performance was assessed by calibration (expected/observed cases) and discriminatory accuracy (C-statistic). RESULTS The expected/observed ratio was 1.01 (95% CI, 0.95 to 1.07). Age-adjusted C-statistics were 0.58 (95% CI, 0.56 to 0.59) overall and 0.63 (95% CI, 0.58 to 0.68) among women younger than 40 years. These measures were almost identical in the model based on estrogen receptor–specific relative risks and attributable risks. CONCLUSION Discriminatory accuracy of the new model was similar to that of the most frequently used questionnaire-based breast cancer risk prediction models in White women, suggesting that effective risk stratification for Black women is now possible. This model may be especially valuable for risk stratification of young Black women, who are below the ages at which breast cancer screening is typically begun.
AB - PURPOSE Breast cancer risk prediction models are used to identify high-risk women for early detection, targeted interventions, and enrollment into prevention trials. We sought to develop and evaluate a risk prediction model for breast cancer in US Black women, suitable for use in primary care settings. METHODS Breast cancer relative risks and attributable risks were estimated using data from Black women in three US population-based case-control studies (3,468 breast cancer cases; 3,578 controls age 30-69 years) and combined with SEER age- and race-specific incidence rates, with incorporation of competing mortality, to develop an absolute risk model. The model was validated in prospective data among 51,798 participants of the Black Women’s Health Study, including 1,515 who developed invasive breast cancer. A second risk prediction model was developed on the basis of estrogen receptor (ER)–specific relative risks and attributable risks. Model performance was assessed by calibration (expected/observed cases) and discriminatory accuracy (C-statistic). RESULTS The expected/observed ratio was 1.01 (95% CI, 0.95 to 1.07). Age-adjusted C-statistics were 0.58 (95% CI, 0.56 to 0.59) overall and 0.63 (95% CI, 0.58 to 0.68) among women younger than 40 years. These measures were almost identical in the model based on estrogen receptor–specific relative risks and attributable risks. CONCLUSION Discriminatory accuracy of the new model was similar to that of the most frequently used questionnaire-based breast cancer risk prediction models in White women, suggesting that effective risk stratification for Black women is now possible. This model may be especially valuable for risk stratification of young Black women, who are below the ages at which breast cancer screening is typically begun.
UR - http://www.scopus.com/inward/record.url?scp=85122166746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122166746&partnerID=8YFLogxK
U2 - 10.1200/JCO.21.01236
DO - 10.1200/JCO.21.01236
M3 - Article
C2 - 34623926
AN - SCOPUS:85122166746
SN - 0732-183X
VL - 39
SP - 3866
EP - 3877
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 34
ER -